title: Liver Metabolic Function of Hemodialysis Patients With Surface Antigen-Positive Hepatitis B.
abstract: OBJECTIVE
  Hepatitis B virus remains a serious problem, particularly for patients with end-stage renal disease on maintenance hemodialysis. This study sought to investigate the levels of serum cholestasis markers in hepatitis B virus-positive patients on maintenance hemodialysis.
  
  
  METHODS
  This study included 50 hepatitis B virus-positive hemodialysis patients (aged 45.4 ± 4.1 years). All patients had been receiving hemodialysis (because of end-stage renal disease) from 2008 to 2009 at the "MedServis" Private Medical Center in Baku, Azerbaijan. We studied serum gamma-glutamyl transpeptidase and alkaline phosphatase levels after the admission (baseline levels) and after 1, 3, and 6 months of beginning of hemodialysis (or observation for control groups-2). The control groups consisted of hepatitis B virus-negative hemodialysis patients (control group-1) and hepatitis B virus-positive patients with end-stage renal disease not requiring hemodialysis (control group-2).
  
  
  RESULTS
  After 1 and 3 months of hemodialysis, serum gamma-glutamyl transpeptidase and alkaline phosphatase levels gradually declined but remained elevated in hepatitis B virus-positive hemodialysis patients compared to control group-1 and control group-2 patients. After 1 month gamma-glutamyl transpeptidase levels in hepatitis B virus-positive hemodialysis patients were 67.9% lower than baseline levels (P0 < .05), were 51.6% higher compared to control group-2 patients (P1 < .05) and did not differ from control group-1 patients (at the same time points). By month 6, serum alkaline phosphatase levels in hepatitis B virus-positive hemodialysis patients had become 53.9% lower than baseline (P < .01), and did not differ from control group-1 and control group-2 patients.
  
  
  CONCLUSIONS
  The data obtained in this study suggest that hemodialysis may have a positive effect on cholestasis in end-stage renal disease patients with hepatitis B virus infection, and may increase immune response and improve liver function in this group of patients.
authors.affiliation: From the "MedServis" Private Medical Center, J. Mammadguluzade st. 3, Baku, AZ1009 Azerbaijan.
authors.forename: Hikmat
authors.initials: H
authors.lastname: Ismailov
authors.forename: Zemfira
authors.initials: Z
authors.lastname: Hasanova
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D001382:Azerbaijan; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D002779:Cholestasis / Q000097:blood / Q000821:virology; D004796:Clinical Enzyme Tests; D005260:Female; D006509:Hepatitis B / Q000097:blood* / Q000150:complications / Q000175:diagnosis / Q000821:virology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D008099:Liver / Q000378:metabolism* / Q000821:virology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors; D016896:Treatment Outcome; D005723:gamma-Glutamyltransferase / Q000097:blood*
chemical_list: D015415:Biomarkers; D005723:gamma-Glutamyltransferase; C554782:gamma-glutamyltransferase, human; D000469:Alkaline Phosphatase